#AbbVie

Several makers of hepatitis C drugs are limiting health care providers’ access to the 340B Drug Pricing Program’s discounts.

A recent study of the direct-acting antiviral regimen included people who contracted hep C within the previous 12 months.

What’s more, reports that Kaletra can fight the novel coronavirus have not been confirmed.

One link between coronaviruses (COVID-19) and the HIV drug Kaletra dates back to the 2003 outbreak of SARS.

Stop me if you’ve heard this one before.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

This finding applies to those with Child-Pugh A cirrhosis who are treated with the Viekira regimen or Technivie, with or without ribavirin.

The two-drug regimen can cure the virus in as little as eight weeks.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

The evening dose of AbbVie’s hepatitis C treatment Viekira Pak may interact harmfully with HIV protease inhibitors.

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.